ELISA tests aid diagnosis of infectious diseases
ORGENTEC Diagnostika has introduced six new tests for the diagnosis of acute, latent and chronic infectious diseases.
The new ELISA tests detect antibodies against Chlamydia trachomatis and Chlamydia pneumoniae. In addition, these test systems make it possible to differentiate between acute, latent, and chronic infection with these widespread bacterial pathogens.
The new tests for the serological diagnosis of Chlamydia were developed specifically for Alegria, ORGENTEC Diagnostika’s random access analyser.
The tests can be used to rapidly, automatically, and economically analyse patient samples for both species of Chlamydia.
- Inclusion of the reagents needed to test a patient sample
- The test kit’s individual barcode contains all of the information required for the analysis and evaluation of the ELISA.
- No preparation of the sample, test strip, or instrument is required before running the test.
The Anti-Chlamydia trachomatis assays use a recombinant antigen of the major outer membrane protein complex (MOMP) of Chlamydia trachomatis.
In addition to the MOMP antigen, these tests use two other recombinant antigens, TARP and CPAF, which also react specifically with antibodies against Chlamydia trachomatis.
The sensitivity and specificity of these tests are thus higher than those of conventional ELISAs, which only use the MOMP target antigen. TARP stands for translocated actin-recruiting protein, CPAF for chlamydial protease-like activity factor.
Several contaminants must be removed from laboratory water to achieve a suitable grade of purity for use with assays.
Myriad RBM has partnered with Bio-Rad to unveil a range of human, rat and canine toxicity panels.
AgPlus has unveiled the first prototype of the handheld diagnostics analytical platform.
Cambridge Research Biochemicals has signed a deal to sell QuickAllAssay labelling reagents in the UK.
The MaxSignal ELISA line improves analysis of nitrofurans in feed, fish, shrimp, meat, honey, milk, serium and urine.